Novartis’ Tekturna faces three month delay
Executive Summary
FDA extends its review of Novartis' NDA for its potential first-in-class oral rennin inhibitor Tekturna (aliskiren) by three months, the company announces Dec. 14. A delay was expected after Novartis said during its R&D day that it was submitting additional data to FDA about the antihypertensive's impact on the colon (1"The Pink Sheet" Dec. 11, 2005, p. 10). Novartis filed aliskiren for both single agent and combination treatment of high blood pressure in the first quarter, setting a late December user fee date. A review extension for Tekturna is the second regulatory setback for Novartis in recent months; the firm announced Nov. 13 that FDA extended the review period for the DPP-4 diabetes agent Galvus (vildagliptin) by three months to assess dermatologic toxicity (2"The Pink Sheet" Dec. 4, 2006, p. 9)...
You may also be interested in...
Novartis Touts Galvus Efficacy Vs. Januvia After Metformin Comparison Fails
Novartis is highlighting the superior efficacy of its dipeptidyl peptidase-4 inhibitor Galvus relative to Merck's recently launched DPP-4 agent Januvia.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.